CC BY 4.0 · TH Open 2021; 05(01): e24-e34
DOI: 10.1055/s-0040-1722611
Original Article

Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE

Carlos Jerjes-Sánchez
1   Tecnologico de Monterrey. Escuela de Medicina y Ciencias de la Salud, Instituto de Cardiologia y Medicina Vascular, TecSalud, Monterrey, Mexico
,
David Rodriguez
1   Tecnologico de Monterrey. Escuela de Medicina y Ciencias de la Salud, Instituto de Cardiologia y Medicina Vascular, TecSalud, Monterrey, Mexico
,
Alfredo E. Farjat
2   Thrombosis Research Institute, London, United Kingdom
,
Gloria Kayani
2   Thrombosis Research Institute, London, United Kingdom
,
Peter MacCallum
2   Thrombosis Research Institute, London, United Kingdom
3   Queen Mary University of London, London, United Kingdom
,
Renato D. Lopes
4   Division of Cardiology, Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, United States
,
Alexander G.G. Turpie
5   McMaster University, Hamilton, Ontario, Canada
,
Jeffrey I. Weitz
5   McMaster University, Hamilton, Ontario, Canada
6   Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
,
Sylvia Haas
7   Formerly Technical University of Munich, Munich, Germany
,
Walter Ageno
8   Department of Medicine and Surgery, University of Insubria, Varese, Italy
,
9   Department of Medicine (Cardiology), Tokai University School of Medicine, Tokai, Japan
,
Samuel Z. Goldhaber
10   Harvard Medical School, Boston, United States
,
Pantep Angchaisuksiri
11   Department of Medicine, Mahidol University, Ramathibodi Hospital, Bangkok, Thailand
,
Joern Dalsgaard Nielsen
12   Copenhagen University Hospital, Copenhagen, Denmark
,
Sebastian Schellong
13   Medical Department, Municipal Hospital, Dresden, Germany
,
Henri Bounameaux
14   Faculty of Medicine, University of Geneva, Geneva, Switzerland
,
Lorenzo G. Mantovani
15   IRCCS Multimedica Milan, Milan, Italy
16   University of Milano, Bicocca, Milan, Italy
,
Paolo Prandoni
17   Arianna Foundation on Anticoagulation, Bologna, Italy
,
Ajay K. Kakkar
18   University College London, London, United Kingdom
,
on behalf of the GARFIELD-VTE investigators › Author Affiliations
Funding The GARFIELD-VTE Registry is an independent academic research initiative sponsored by the Thrombosis Research Institute (London, UK) and supported by an unrestricted research grant from Bayer Pharma AG (Berlin, Germany).

Abstract

Introduction The risk of venous thromboembolism (VTE) increases during pregnancy and the puerperium such that VTE is a leading cause of maternal mortality.

Methods We describe the clinical characteristics, diagnostic strategies, treatment patterns, and outcomes of women with pregnancy-associated VTE (PA-VTE) enrolled in the Global Anticoagulant Registry in the FIELD (GARFIELD)-VTE. Women of childbearing age (<45 years) were stratified into those with PA-VTE (n = 183), which included pregnant patients and those within the puerperium, and those with nonpregnancy associated VTE (NPA-VTE; n = 1,187). Patients with PA-VTE were not stratified based upon the stage of pregnancy or puerperium.

Results Women with PA-VTE were younger (30.5 vs. 34.8 years), less likely to have pulmonary embolism (PE) (19.7 vs. 32.3%) and more likely to have left-sided deep vein thrombosis (DVT) (73.9 vs. 54.8%) compared with those with NPA-VTE. The most common risk factors in PA-VTE patients were hospitalization (10.4%), previous surgery (10.4%), and family history of VTE (9.3%). DVT was typically diagnosed by compression ultrasonography (98.7%) and PE by chest computed tomography (75.0%). PA-VTE patients more often received parenteral (43.2 vs. 15.1%) or vitamin K antagonists (VKA) (9.3 vs. 7.6%) therapy alone. NPA-VTE patients more often received a DOAC alone (30.2 vs. 13.7%). The risk (hazard ratio [95% confidence interval]) of all-cause mortality (0.59 [0.18–1.98]), recurrent VTE (0.82 [0.34–1.94]), and major bleeding (1.13 [0.33–3.90]) were comparable between PA-VTE and NPA-VTE patients. Uterine bleeding was the most common complication in both groups.

Conclusion VKAs or DOACs are widely used for treatment of PA-VTE despite limited evidence for their use in this population. Rates of clinical outcomes were comparable between groups.

Note

Independent ethics committee and hospital-based institutional review board approvals were obtained, as necessary, for the registry protocol. Patient consent has also been obtained. The lead authors affirm that the manuscript is an honest, accurate, and transparent account of the study being reported, that no important aspects of the study have been omitted.


* A full list of investigators is given in the [Supplementary Material].


Supplementary Material



Publication History

Received: 13 November 2020

Accepted: 30 November 2020

Article published online:
27 January 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124 (12) 1968-1975
  • 2 Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton III LJ. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143 (10) 697-706
  • 3 Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008; 6 (04) 632-637
  • 4 Jerjes-Sánchez C, García-Sosa A. Thrombolysis in Special Situations. 2015: 211-227
  • 5 Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. N Engl J Med 2008; 359 (19) 2025-2033
  • 6 James AH. Venous thromboembolism in pregnancy. Arterioscler Thromb Vasc Biol 2009; 29 (03) 326-331
  • 7 Kamel H, Navi BB, Sriram N, Hovsepian DA, Devereux RB, Elkind MS. Risk of a thrombotic event after the 6-week postpartum period. N Engl J Med 2014; 370 (14) 1307-1315
  • 8 James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006; 194 (05) 1311-1315
  • 9 Bates SM, Middeldorp S, Rodger M, James AH, Greer I. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis 2016; 41 (01) 92-128
  • 10 James A. Committee on Practice Bulletins—Obstetrics. Practice bulletin no. 123: thromboembolism in pregnancy. Obstet Gynecol 2011; 118 (03) 718-729
  • 11 Bates SM, Greer IA, Middeldorp S. et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl. 02) e691S-e736S
  • 12 Gynaecologists RCoOa. Green-top Guideline No. 37a. Reducing the risk of thrombosis and embolism during pregnancy and the puerperium. Accessed July 18, 2019 at: https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg37a/
  • 13 Konstantinides SV, Meyer G, Becattini C. et al; The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J 2019; 54 (03) 2019
  • 14 Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) 627S-644S
  • 15 Cohen H, Arachchillage DR, Middeldorp S, Beyer-Westendorf J, Abdul-Kadir R. Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14 (08) 1673-1676
  • 16 Saito J, Kaneko K, Yakuwa N, Kawasaki H, Yamatani A, Murashima A. Rivaroxaban concentration in breast milk during breastfeeding: a case study. Breastfeed Med 2019; 14 (10) 748-751
  • 17 Wiesen MH, Blaich C, Müller C, Streichert T, Pfister R, Michels G. The direct factor Xa inhibitor rivaroxaban passes into human breast milk. Chest 2016; 150 (01) e1-e4
  • 18 Zhao Y, Ding A, Arya R, Patel JP. Factors influencing the recruitment of lactating women in a clinical trial involving direct oral anticoagulants: a qualitative study. Int J Clin Pharm 2018; 40 (06) 1511-1518
  • 19 Weitz JI, Haas S, Ageno W. et al. Global anticoagulant registry in the field - venous thromboembolism (GARFIELD-VTE). Rationale and design. Thromb Haemost 2016; 116 (06) 1172-1179
  • 20 Ageno W, Haas S, Weitz JI. et al; GARFIELD-VTE investigators. Characteristics and management of patients with venous thromboembolism: the GARFIELD-VTE registry. Thromb Haemost 2019; 119 (02) 319-327
  • 21 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
  • 22 Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv 1999; 54 (04) 265-271
  • 23 Cockett FB, Thomas ML. The iliac compression syndrome. Br J Surg 1965; 52 (10) 816-821
  • 24 Cavalcante LP, Souza JEDS, Pereira RM. et al. Iliac vein compression syndrome: literature review. J Vasc Bras 2015; 14: 78-83
  • 25 McColl MD, Ramsay JE, Tait RC. et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78 (04) 1183-1188
  • 26 Danilenko-Dixon DR, Heit JA, Silverstein MD. et al. Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: a population-based, case-control study. Am J Obstet Gynecol 2001; 184 (02) 104-110
  • 27 Simcox LE, Ormesher L, Tower C, Greer IA. Pulmonary thrombo-embolism in pregnancy: diagnosis and management. Breathe (Sheff) 2015; 11 (04) 282-289
  • 28 Mazzolai L, Aboyans V, Ageno W. et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J 2018; 39 (47) 4208-4218
  • 29 Lockwood CJ. Inherited thrombophilias in pregnant patients: detection and treatment paradigm. Obstet Gynecol 2002; 99 (02) 333-341
  • 30 Wells PS, Anderson DR, Bormanis J. et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 1997; 350 (9094): 1795-1798
  • 31 Kearon C, Julian JA, Newman TE, Ginsberg JS. Noninvasive diagnosis of deep venous thrombosis. McMaster diagnostic imaging practice guidelines initiative. Ann Intern Med 1998; 128 (08) 663-677
  • 32 Fraser DG, Moody AR, Morgan PS, Martel AL, Davidson I. Diagnosis of lower-limb deep venous thrombosis: a prospective blinded study of magnetic resonance direct thrombus imaging. Ann Intern Med 2002; 136 (02) 89-98
  • 33 Leung AN, Bull TM, Jaeschke R. et al; ATS/STR Committee on Pulmonary Embolism in Pregnancy. An official American Thoracic Society/Society of Thoracic Radiology clinical practice guideline: evaluation of suspected pulmonary embolism in pregnancy. Am J Respir Crit Care Med 2011; 184 (10) 1200-1208
  • 34 Gynaecologists RCoOa. Green-top Guideline No. 37b. Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management. Accessed August 16, 2019 at: https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37b.pdf
  • 35 Rodriguez D, Jerjes-Sanchez C, Fonseca S. et al. Thrombolysis in massive and submassive pulmonary embolism during pregnancy and the puerperium: a systematic review. J Thromb Thrombolysis 2020; 50 (04) 929-941
  • 36 Bates SM, Rajasekhar A, Middeldorp S. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv 2018; 2 (22) 3317-3359
  • 37 Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106 (02) 401-407
  • 38 Kearon C, Akl EA, Ornelas J. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
  • 39 Alshawabkeh L, Economy KE, Valente AM. Anticoagulation during pregnancy: evolving strategies with a focus on mechanical valves. J Am Coll Cardiol 2016; 68 (16) 1804-1813
  • 40 Maas AH, Euler Mv, Bongers MY. et al. Practice points in gynecardiology: abnormal uterine bleeding in premenopausal women taking oral anticoagulant or antiplatelet therapy. Maturitas 2015; 82 (04) 355-359